Precision Medicine in Oncology®

A major step toward improved tolerability of cisplatin-based therapy came in the early 2000s with the advent of the modern regimen of gemcitabine and cisplatin.

A number of large pharmaceutical companies have forged clinical trial collaborations focused on the investigation of novel combinations and companion diagnostics across multiple cancer indications.

A genomic analysis of renal cell carcinoma (RCC) has uncovered new clues about the development, growth, and spread of the cancer.

Suzanne A. W. Fuqua, PhD, professor of medicine at Baylor College of Medicine, discusses the Y537 hotspot in breast cancer.

Selena Juarez Stuart, MD, hematology/oncology fellow, Cancer Therapy & Research Center, The University of Texas Health Science Center at San Antonio, discusses the risks and benefits of phase I liver dysfunction studies.

Andrew R. Allen, BM, BCh, MA, MRCP, PhD, Executive Vice President of Clinical and Pre-Clinical Development, Chief Medical Officer, Co-Founder, Clovis Oncology, provides an overview of CO-1686.

Settlemen addressed broad questions about his research into acquired resistance mechanisms in an interview with OncologyLive.

When it comes to the personalized treatment of genitourinary cancers, biomarkers hold an immense amount of promise. Already, there are predictive and prognostic tools available to urologists.

David R. Gandara, MD, Professor of Medicine, Division of Hematology and Oncology, Director, Thoracic Oncology Program, Associate Director, Clinical Research, UC Davis Comprehensive Cancer Center, discusses examining third-generation EGFR TKIs in lung cancer.

Hailed as "new ammunition in the war against cancer" and featured in TIME magazine at the turn of the new millennium, molecularly targeted therapies have gone on to revolutionize cancer treatment. Clinical responses, however, are all too often short-lived as cancer cells become resistant.

Women harboring a loss-of-function mutation in the PALB2 gene demonstrated an increased risk of developing breast cancer that was similar to the predisposition seen with mutations in the infamous BRCA gene

Nobody disputes the need for careful, judicious diagnostic testing. But as the number of individual gene tests continues to grow, clinicians are struggling to keep up. On the one hand, using diagnostic markers like KRAS in colon cancer or hormone receptor status in breast cancer to select the most appropriate chemotherapy regimen is essential.

Third generation EGFR TKIs have demonstrated dramatic benefits for patients with non-small cell lung cancer (NSCLC) and should be considered as a standard second-line option following resistance to frontline therapy

Fred R. Hirsch, MD, PhD Professor of Medicine and Pathology, Associate Director for International Programs, University of Colorado Cancer Center, discusses the role of next-generation EGFR inhibitors.